Vaximm
Vaximm is developing oral T-cell immunotherapies to treat cancer patients.
1
Funding Rounds
$8.0m
Money raised
Overview
Vaximm is developing oral T-cell immunotherapies to treat cancer patients.
- Website:
- Social accounts: linkedin
Funding series
Funding Series Analysis
The company Vaximm has raised a total of $8m in funding over 1 rounds.
Key Insights:
- Vaximm funding round, January 2011: $8m
Vaximm funding round, January 2011
$8m
Industries
Vaximm is active in the following industries: